insights

COVID-19 Vaccine Updates and Latest Information

In the June webinar, our final webinar in this series, IFM’s COVID-19 Update: Fatigue, Immunomodulation, and Post-acute Sequelae of SARS-CoV-2 (PASC), members of the IFM COVID-19 task force, Robert Luby, MD; Patrick Hanaway, MD; and Joel Evans, MD, along with guest presenters, presented an overview of the underlying biochemical imbalances that may result in fatigue and immune dysregulation and provided treatment approaches including a case presentation. The presenters also shared the latest updates on COVID-19 vaccines and addressed questions and concerns surrounding them.

The recording of this webinar, along with the webinars for February, March, April, and May are available below. They were part of a monthly series updating practitioners about the latest medical research on mitigating SARS-CoV-2 infection and addressing Post-Acute Sequelae of SARS-CoV-2 (PASC) as a component of IFM’s Resistance, Resilience, and Recovery: Patient Care in a Pandemic online course. Due to the diminishing need for information related to acute SARS-CoV-2 infection, this course is no longer available for purchase.

June 2021
JUNE TRANSCRIPT
March 2021
MARCH TRANSCRIPT
February 2021
FEBRUARY TRANSCRIPT

As discussed by the panelists, in order to properly assess each vaccine, IFM has created this informational dashboard for each approved vaccine, as well as those in phase 3 clinical trials. We continue to monitor outcomes data for each vaccine after its initial release and will update this dashboard accordingly.

Click on table to zoom

References

  1. US Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 vaccine. Revised August 30, 2021. Accessed September 8, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-va­ccine
  2. Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. Updated September 8, 2021. Accessed September 9, 2021. https://covid.cdc.gov/covid-data-tracker/#vaccinations
  3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  4. Jenco M. AAP, CDC recommend COVID-19 vaccine for ages 12 and older. AAP News and Journals. Published May 12, 2021. Accessed May 13, 2021. https://www.aappublications.org/news/2021/05/12/cdc-aap-pfizer-covid-vaccine-teens-051221
  5. Perez JL. COVID-19 vaccine BNT162b2: safety, immunogenicity, and efficacy in subjects 12-15 years-old. Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/02-COVID-Perez-508.pdf
  6. US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised August 27, 2021. Accessed February 12, 2021. https://www.fda.gov/media/144637/download
  7. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
  8. US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee meeting February 26, 2021: FDA briefing document Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. Revised February 26, 2021. Accessed February 28, 2021. https://www.fda.gov/media/146217/download
  9. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544
  10. Medicines & Healthcare Products Regulatory Agency. Decision: summary of product characteristics for Vaxzevria. Updated September 9, 2021. Accessed September 9, 2021. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca
  11. European Medicines Agency. EMA recommends COVID-19 vaccine AstraZeneca for authorisation in the EU. Updated January 29, 2021. Accessed March 12, 2021. https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu#:~:text=COVID%2D19%20Vaccine%20AstraZeneca%20is,Commission%20on%2029%20January%202021.&text=This%20is%20the%20third%20COVID,EMA%20has%20recommended%20for%20authorisation
  12. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet. 2021; 397(10269):98]. Lancet. 2021;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1
  13. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi:10.1016/S0140-6736(21)00234-8
  14. Novavax. Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial. Published June 14, 2021. Accessed June 16, 2021. https://ir.novavax.com/2021-06-14-Novavax-COVID-19-Vaccine-Demonstrates-90-Overall-Efficacy-and-100-Protection-Against-Moderate-and-Severe-Disease-in-PREVENT-19-Phase-3-Trial
  15. World Health Organization. Tracking SARS-CoV-2 variants. Updated September 2, 2021. Accessed September 8, 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  17. Mahase E. COVID-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows. BMJ. 2020;371:m4826. doi:10.1136/bmj.m4826
  18. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7
  19. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; preliminary study. MedRxiv. Updated July 31, 2021. Accessed September 8, 2021. https://www.medrxiv.org/content/10.1101/2021.07.29.21261317v1
  20. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
  21. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790-792. doi:10.1038/s41591-021-01316-7
  22. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant – National Healthcare Safety Network, March 1 – August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-1166. doi:10.15585/mmwr.mm7034e3
  23. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status – New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1150-1155. doi:10.15585/mmwr.mm7034e1
  24. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. Published online September 1, 2021. doi:10.1016/S1473-3099(21)00460-6
  25. Pfizer. Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Published April 1, 2021, Accessed April 15, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
  26. Centers for Disease Control and Prevention. Science brief: COVID-19 vaccines and vaccination. Updated July 27, 2021. Accessed September 9, 2021. https://www.cdc.gov/coronavirus/2019-ncov/more/fully-vaccinated-people.html#ref29
  27. Parry HM, Tut G, Faustini S, et al. BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralization of P.1 Brazilian variant. Updated March 31, 2021. Accessed April 15, 2021. doi:10.2139/ssrn.3816840
  28. Liu Y, Liu J, Xia H, et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021;385(5)472-474. doi:10.1056/NEJMc2106083
  29. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273-275. doi:10.1038/s41586-021-03693-y
  30. Centers for Disease Control and Prevention. Delta variant: what we know about the science. Updated August 26, 2021. Accessed Sept 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
  31. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-594. doi:10.1056/NEJMoa2108891
  32. Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med. Published online September 1, 2021. doi:10.1056/NEJMc2112981
  33. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. MedRxiv. Published August 24, 2021. Accessed September 8, 2021. https://www.medrxiv.org/content/10.1101/2021.08.18.21262237v1
  34. Centers for Disease Control and Prevention. The Vaccine Adverse Reporting System (VAERS) results. Accessed February 12, 2021. https://wonder.cdc.gov/vaers.html
  35. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51. doi.10.15585/mmwr.mm7002e1
  36. Tamaki A, Cabrera CI, Li S, et al. Incidence of Bell palsy in patients with COVID-19. JAMA Otolaryngol Head Neck Surg. 2021;147(8):767-768. doi:10.1001/jamaoto.2021.1266
  37. Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. Science. Published June 1, 2021. Accessed September 8, 2021. https://www.science.org/news/2021/06/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination
  38. Thompson MG, Burgess JL, Naleway Al, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV2 infection among health care personnel, first responders, and other essential and frontline workers – eight U.S. locations, December 2020 – March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3
  39. Wu K, Werner AP, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384(15):1468-1470. doi:10.1056/NEJMc2102179
  40. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129. doi:10.15585/mmwr.mm7004e1
  41. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384(19):1824-1835. doi:10.1056/NEJMoa2034201
  42. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964-1965. doi:10.1056/NEJMc2105869
  43. American Society of Hematology. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). Updated August 12, 2021. Accessed September 9, 2021. https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
  44. Shimabukuro T; CDC COVID-19 Vaccine Task Force. Update: thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. Advisory committee on immunization practices (ACIP). Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf
  45. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3
  46. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885-1898. doi:10.1056/NEJMoa2102214
  47. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. doi:10.1016/S0140-6736(20)32623-4
  48. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi:10.1056/NEJMoa2104840
  49. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Updated April 7, 2021. Accessed April 15, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
  50. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899-1909. doi:10.1056/NEJMoa2103055
  51.  Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924. doi:10.15585/mmwr.mm6950e2
  52.  Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273-2282. doi:10.1056/NEJMoa2104983
  53.  Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653-1656. doi:10.15585/mmwr.mm695152e1